Cargando…

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma

BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is an important treatment for T-cell lymphoblastic lymphoma/leukemia (T-LBL). To compare the efficacy and influencing factors of autologous hematopoietic stem cell transplantation (auto-HSCT) with those of allogeneic hematopoietic stem cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhen, Zhang, Binglei, Fan, Xinxin, Gui, Ruirui, Yu, Fengkuan, Wang, Juan, Zhang, Yanli, Zhou, Keshu, Liu, Yanyan, Li, Yufu, Ding, Jing, Song, Yongping, Zhou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399448/
https://www.ncbi.nlm.nih.gov/pubmed/37546390
http://dx.doi.org/10.3389/fonc.2023.1193237
_version_ 1785084243659980800
author Li, Zhen
Zhang, Binglei
Fan, Xinxin
Gui, Ruirui
Yu, Fengkuan
Wang, Juan
Zhang, Yanli
Zhou, Keshu
Liu, Yanyan
Li, Yufu
Ding, Jing
Song, Yongping
Zhou, Jian
author_facet Li, Zhen
Zhang, Binglei
Fan, Xinxin
Gui, Ruirui
Yu, Fengkuan
Wang, Juan
Zhang, Yanli
Zhou, Keshu
Liu, Yanyan
Li, Yufu
Ding, Jing
Song, Yongping
Zhou, Jian
author_sort Li, Zhen
collection PubMed
description BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is an important treatment for T-cell lymphoblastic lymphoma/leukemia (T-LBL). To compare the efficacy and influencing factors of autologous hematopoietic stem cell transplantation (auto-HSCT) with those of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from different donors for the treatment of T-cell lymphoblastic lymphoma/leukemia (T-LBL) and provide a basis for selection of appropriate transplant methods and donors. METHODS: To provide evidence of appropriate transplant methods for these patients, we retrospectively summarized the clinical characteristics of 75 T-LBL patients receiving HSCT at Henan Cancer Hospital between March 2012 and October 2021. Overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and related factors affecting efficacy were analyzed. RESULTS: The 3-year CIR (39.9% vs 31.1%, P=0.745), 3-year PFS (60.1% vs 49.6%, P=0.434), and 3-year OS (62.8% vs 53.0%, P=0.450) were not significantly different between the auto-HSCT and allo-HSCT groups. However, the 3-year NRM was significantly higher in the allo-HSCT group (0% vs 27.2%, P=0.033). Multivariate analysis showed that the first complete remission (CR1) after HSCT was an independent influencing factor of higher OS (HR=2.498, P=0.029) and PFS (HR=2.576, P=0.016). The absence of mediastinal invasion in patients receiving HSCT was an independent influencing factor of better PFS (HR=2.977, P=0.029) and lower CIR (HR=4.040, P=0.027). With respect to the impact of donor source, the NRM in the unrelated donor (URD) and haploid donor (HPD) groups was significantly higher than that in the auto-HSCT group (P=0.021 and P=0.003, respectively), while there was no significant difference between matched sibling donors (MSD) and auto-HSCT. Compared with the MSD-HSCT group, the auto-HSCT group showed an increasing trend in 3-year CIR (39.9 ± 11.1% vs 32.6 ± 11.2%, P=0.697) and a lower trend in 3-year OS (62.8 ± 11.4% vs 64.4 ± 12.2%, P=0.929). CONCLUSIONS: HSCT is an effective consolidation treatment option for patients with T-LBL without mediastinal invasion and with CR1 before transplantation. For CR1 patients, auto-HSCT and MSD-HSCT are effective modalities for improving survival. In non-CR1 patients without an MSD, matched unrelated donors and haploidentical donor transplantations are the best treatment options to reduce relapse and improve prognosis.
format Online
Article
Text
id pubmed-10399448
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103994482023-08-04 Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma Li, Zhen Zhang, Binglei Fan, Xinxin Gui, Ruirui Yu, Fengkuan Wang, Juan Zhang, Yanli Zhou, Keshu Liu, Yanyan Li, Yufu Ding, Jing Song, Yongping Zhou, Jian Front Oncol Oncology BACKGROUND: Hematopoietic stem cell transplantation (HSCT) is an important treatment for T-cell lymphoblastic lymphoma/leukemia (T-LBL). To compare the efficacy and influencing factors of autologous hematopoietic stem cell transplantation (auto-HSCT) with those of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from different donors for the treatment of T-cell lymphoblastic lymphoma/leukemia (T-LBL) and provide a basis for selection of appropriate transplant methods and donors. METHODS: To provide evidence of appropriate transplant methods for these patients, we retrospectively summarized the clinical characteristics of 75 T-LBL patients receiving HSCT at Henan Cancer Hospital between March 2012 and October 2021. Overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and related factors affecting efficacy were analyzed. RESULTS: The 3-year CIR (39.9% vs 31.1%, P=0.745), 3-year PFS (60.1% vs 49.6%, P=0.434), and 3-year OS (62.8% vs 53.0%, P=0.450) were not significantly different between the auto-HSCT and allo-HSCT groups. However, the 3-year NRM was significantly higher in the allo-HSCT group (0% vs 27.2%, P=0.033). Multivariate analysis showed that the first complete remission (CR1) after HSCT was an independent influencing factor of higher OS (HR=2.498, P=0.029) and PFS (HR=2.576, P=0.016). The absence of mediastinal invasion in patients receiving HSCT was an independent influencing factor of better PFS (HR=2.977, P=0.029) and lower CIR (HR=4.040, P=0.027). With respect to the impact of donor source, the NRM in the unrelated donor (URD) and haploid donor (HPD) groups was significantly higher than that in the auto-HSCT group (P=0.021 and P=0.003, respectively), while there was no significant difference between matched sibling donors (MSD) and auto-HSCT. Compared with the MSD-HSCT group, the auto-HSCT group showed an increasing trend in 3-year CIR (39.9 ± 11.1% vs 32.6 ± 11.2%, P=0.697) and a lower trend in 3-year OS (62.8 ± 11.4% vs 64.4 ± 12.2%, P=0.929). CONCLUSIONS: HSCT is an effective consolidation treatment option for patients with T-LBL without mediastinal invasion and with CR1 before transplantation. For CR1 patients, auto-HSCT and MSD-HSCT are effective modalities for improving survival. In non-CR1 patients without an MSD, matched unrelated donors and haploidentical donor transplantations are the best treatment options to reduce relapse and improve prognosis. Frontiers Media S.A. 2023-07-20 /pmc/articles/PMC10399448/ /pubmed/37546390 http://dx.doi.org/10.3389/fonc.2023.1193237 Text en Copyright © 2023 Li, Zhang, Fan, Gui, Yu, Wang, Zhang, Zhou, Liu, Li, Ding, Song and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Zhen
Zhang, Binglei
Fan, Xinxin
Gui, Ruirui
Yu, Fengkuan
Wang, Juan
Zhang, Yanli
Zhou, Keshu
Liu, Yanyan
Li, Yufu
Ding, Jing
Song, Yongping
Zhou, Jian
Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
title Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
title_full Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
title_fullStr Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
title_full_unstemmed Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
title_short Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
title_sort selection of hematopoietic stem cell transplantation for t-cell lymphoblastic lymphoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399448/
https://www.ncbi.nlm.nih.gov/pubmed/37546390
http://dx.doi.org/10.3389/fonc.2023.1193237
work_keys_str_mv AT lizhen selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT zhangbinglei selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT fanxinxin selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT guiruirui selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT yufengkuan selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT wangjuan selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT zhangyanli selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT zhoukeshu selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT liuyanyan selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT liyufu selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT dingjing selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT songyongping selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma
AT zhoujian selectionofhematopoieticstemcelltransplantationfortcelllymphoblasticlymphoma